Twenty four participants aged 35 to 70 years with impaired fasting glucose (100mg/dl-125 mg/dl) will be studied. We will screen up to twice that number i.e. 48 which will allow for dropouts or screen failures. Individuals with a body mass index less than 19 or greater than 40 kg/m2, or a total weight > 130kg, will be excluded from study to avoid potential confounding effects that may result from extreme leanness or obesity. Subjects greater than age 35 years of age will be eligible for study. Subjects less than 35 years will not be studied in order to minimize the possibility of studying subjects with type 1 diabetes. Subjects must be in good health as determined by past medical history and a physical examination inclusive vital signs, electrocardiogram, and laboratory tests at the time of screening. Healthy subjects will mean that the participant has no history of a) significant nephropathy, (i.e., plasma creatinine > 1.4 mg/dl in women and 1.5 mg/dl in men, and/or proteinuria); b) clinically significant atherosclerotic vascular disease (e.g., history of MI or angina); c) a known systemic illness. Patients on diuretics or thyroid hormone therapy must be on a stable dose (at least 3 months prior to screening) and the maintenance dose may not be adjusted during the study